A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine

被引：0

作者：

Croop, R. ^{[1
]}

Lipton, R. B. ^{[2
]}

Kudrow, D. ^{[3
]}

Stock, D. A. ^{[1
]}

Kamen, L. ^{[1
]}

Conway, C. M. ^{[1
]}

Stock, E. G. ^{[1
]}

Coric, V. ^{[1
]}

Goadsby, P. J. ^{[4
,5
]}

机构：

[1] Biohaven Pharmaceut, New Haven, CT USA

[2] Albert Einstein Coll Med, Bronx, NY 10467 USA

[3] Calif Med Clin Headache, Santa Monica, CA USA

[4] Kings Coll Hosp London, NIHR Wellcome Trust Kings Clin Res Facil, SLaM Biomed Res Ctr, Kings Coll, London, England

[5] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA

来源：

JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

AL054

引用

页码：19 / 19

页数：1

共 50 条

[31] Efficacy, safety, and tolerability of rimegepant 75 mg orally dissolving tablet for the acute treatment of migraine: Results from a phase 3, double-blind, randomized, placebo-controlled trial, Study 303
Lipton, Richard B.
Coric, Vladimir
Stock, Elyse
Stock, David
Thiry, Alexandra
Conway, Charles
Dubowchik, Gene
Jensen, Christopher
Gosden, Ralph
Frost, Marianne
Gentile, Kimberly
Morris, Beth
Forshaw, Micaela
Croop, Robert
NEUROLOGY, 2019, 93 (05) : E532 - E532
[32] A Randomized, Double-Blind, Placebo-Controlled Study of Fremanezumab for the Preventive Treatment of Migraine in Chinese Adults: Study Protocol
Ning, Xiaoping
Barash, Steve
Roth-Ben Arie, Zipora
Campos, Verena Ramirez
Krasenbaum, Lynda J.
Ahn, Andrew H.
CEPHALALGIA, 2023, 43 (1supp) : 60 - 60
[33] Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
Lipton, Richard B.
Thiry, Alexandra
Morris, Beth A.
Croop, Robert
JOURNAL OF PAIN RESEARCH, 2024, 17 : 2431 - 2441
[34] Efficacy and safety of acetaminophen in the treatment of migraine -: Results of a randomized, double-blind, placebo-controlled, population-based study
Lipton, RB
Baggish, JS
Stewart, WF
Codispoti, JR
Fu, M
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (22) : 3486 - 3492
[35] Haloperidol in the acute treatment of migraine: A randomized, double-blind, placebo-controlled study
Honkaniemi, J
Liimatainen, S
Rainesalo, S
Sulavuori, S
HEADACHE, 2006, 46 (05): : 781 - 787
[36] A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia
Elhilali, MM
Ramsey, EW
Barkin, J
Casey, RW
Boake, RC
Beland, G
Fradet, Y
Trachtenberg, J
Orovan, WL
Schick, E
Klotz, LH
UROLOGY, 1996, 47 (03) : 335 - 342
[37] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
Hu, Bo
Li, Gang
Li, Xiaohong
Wu, Shan
Yu, Tingmin
Li, Xiang
Zhao, Hongru
Jia, Zhihua
Zhuang, Junpeng
Yu, Shengyuan
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
[38] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
Bo Hu
Gang Li
Xiaohong Li
Shan Wu
Tingmin Yu
Xiang Li
Hongru Zhao
Zhihua Jia
Junpeng Zhuang
Shengyuan Yu
The Journal of Headache and Pain, 2022, 23
[39] Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of prucalopride in pediatric patients with functional constipation
Cuffari, Carmen
Spalding, William
Achenbach, Heinrich
Thakur, Manoj
Gabriel, Andre
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
[40] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and afety of Erenumab in Migraine Prevention: Primary Results of the ARISE Trial
Dodick, D. W.
Ashina, M.
Kudrow, D.
Lanteri-Minet, M.
Osipova, V
Palmer, K.
Picard, H.
Mikol, D. D.
Lenz, R. A.
HEADACHE, 2017, 57 : 191 - 192

← 1 2 3 4 5 →